Pakistan Drug Makers Subject To License Review After DRAP Created
This article was originally published in PharmAsia News
Drug makers in Pakistan are to be subjected to re-evaluations of their production licenses and renewals as a result of the Drug Regulatory Agency of Pakistan Ordinance.
You may also be interested in...
Work and movement-related restrictions are affecting the ability of companies to provide a timely response to questions relating to their prequalification dossiers.
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.